Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib DDI Study in Advanced Solid Tumors
NCT02740712Phase 1Completed
- Sponsor
- pharma&
- Start
- Apr 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rucaparib in solid tumor (advanced stage), sponsored by pharma&. Primary endpoint: PK parameters for caffeine, S-warfarin, omeprazole, midazolam, and digoxin. Started Apr 2016; status: completed.
02
Drugs
rucaparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02740712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740712.